This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
TCR2 Therapeutics 미래 성장
Future 기준 확인 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for TCR2 Therapeutics.
주요 정보
-0.2%
수익 성장률
25.3%
EPS 성장률
| Biotechs 수익 성장 | 24.1% |
| 매출 성장률 | 74.9% |
| 향후 자기자본 수익률 | n/a |
| 애널리스트 커버리지 | Low |
| 마지막 업데이트 | 02 Jun 2023 |
최근 미래 성장 업데이트
Recent updates
Here's Why TCR2 Therapeutics (NASDAQ:TCRR) Must Use Its Cash Wisely
Mar 08
Can TCR2 Therapeutics (NASDAQ:TCRR) Afford To Invest In Growth?
Nov 23TCR² Therapeutics: Betting On A Solid Reversal
Aug 18TCR2 Therapeutics GAAP EPS of -$0.82 misses by $0.02
Aug 08We Think TCR2 Therapeutics (NASDAQ:TCRR) Needs To Drive Business Growth Carefully
Jun 08We Think TCR2 Therapeutics (NASDAQ:TCRR) Can Afford To Drive Business Growth
Jan 11TCR2 Therapeutics: Trading Below Cash
Jan 06TCR2 Therapeutics: Trading Near Cash Value
Oct 12Is There An Opportunity With TCR2 Therapeutics Inc.'s (NASDAQ:TCRR) 26% Undervaluation?
Sep 02TCR2 Therapeutics - Promising Technology And Upside Potential
Jun 15Companies Like TCR2 Therapeutics (NASDAQ:TCRR) Are In A Position To Invest In Growth
Jun 04Who Has Been Selling TCR2 Therapeutics Inc. (NASDAQ:TCRR) Shares?
Feb 19
TCR2 Therapeutics (NASDAQ:TCRR) Is In A Good Position To Deliver On Growth Plans
Dec 28TCR2 Therapeutics share slumps 11%, announces response for Phase 1/2 Trial of TC-210
Dec 14TCR2 Therapeutics reports Q3 results
Nov 12TCR² Therapeutics teams up with ElevateBio to expand TC-210 manufacturing capacity
Nov 10수익 및 매출 성장 예측
| 날짜 | 수익 | 수익 | 잉여 현금 흐름 | 작전 현금 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2025 | 13 | -235 | N/A | N/A | 1 |
| 12/31/2024 | N/A | -136 | N/A | N/A | 2 |
| 12/31/2023 | N/A | -139 | N/A | N/A | 3 |
| 3/31/2023 | N/A | -163 | -124 | -110 | N/A |
| 12/31/2022 | N/A | -152 | -117 | -101 | N/A |
| 9/30/2022 | N/A | -119 | -120 | -100 | N/A |
| 6/30/2022 | N/A | -115 | -111 | -93 | N/A |
| 3/31/2022 | N/A | -107 | -101 | -89 | N/A |
| 12/31/2021 | N/A | -100 | -93 | -82 | N/A |
| 9/30/2021 | N/A | -91 | -81 | -72 | N/A |
| 6/30/2021 | N/A | -81 | -72 | -63 | N/A |
| 3/31/2021 | N/A | -73 | -72 | -64 | N/A |
| 12/31/2020 | N/A | -67 | -64 | -57 | N/A |
| 9/30/2020 | N/A | -61 | -57 | -54 | N/A |
| 6/30/2020 | N/A | -58 | -57 | -53 | N/A |
| 3/31/2020 | N/A | -53 | -51 | -47 | N/A |
| 12/31/2019 | N/A | -97 | -45 | -41 | N/A |
| 9/30/2019 | N/A | -96 | -41 | -37 | N/A |
| 6/30/2019 | N/A | -100 | -33 | -32 | N/A |
| 3/31/2019 | N/A | -107 | -27 | -27 | N/A |
| 12/31/2018 | N/A | -62 | -20 | -19 | N/A |
| 9/30/2018 | N/A | -55 | -18 | -17 | N/A |
| 12/31/2017 | N/A | -15 | -12 | -12 | N/A |
애널리스트 미래 성장 예측
수입 대 저축률: TCRR is forecast to remain unprofitable over the next 3 years.
수익 vs 시장: TCRR is forecast to remain unprofitable over the next 3 years.
고성장 수익: TCRR is forecast to remain unprofitable over the next 3 years.
수익 대 시장: TCRR is forecast to have no revenue next year.
고성장 수익: TCRR is forecast to have no revenue next year.
주당 순이익 성장 예측
미래 자기자본 수익률
미래 ROE: Insufficient data to determine if TCRR's Return on Equity is forecast to be high in 3 years time